AU2009333433B2 - Compounds useful for inhibiting Chk1 - Google Patents

Compounds useful for inhibiting Chk1 Download PDF

Info

Publication number
AU2009333433B2
AU2009333433B2 AU2009333433A AU2009333433A AU2009333433B2 AU 2009333433 B2 AU2009333433 B2 AU 2009333433B2 AU 2009333433 A AU2009333433 A AU 2009333433A AU 2009333433 A AU2009333433 A AU 2009333433A AU 2009333433 B2 AU2009333433 B2 AU 2009333433B2
Authority
AU
Australia
Prior art keywords
cancer
compound
salt
pyrazol
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009333433A
Other languages
English (en)
Other versions
AU2009333433A1 (en
Inventor
Francine S. Farouz
Ryan Coatsworth Holcomb
Ramesh Kasar
Steven Scott Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2009333433A1 publication Critical patent/AU2009333433A1/en
Application granted granted Critical
Publication of AU2009333433B2 publication Critical patent/AU2009333433B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2009333433A 2008-12-17 2009-12-10 Compounds useful for inhibiting Chk1 Ceased AU2009333433B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17
US61/138,176 2008-12-17
PCT/US2009/067437 WO2010077758A1 (en) 2008-12-17 2009-12-10 Compounds useful for inhibiting chk1

Publications (2)

Publication Number Publication Date
AU2009333433A1 AU2009333433A1 (en) 2011-06-30
AU2009333433B2 true AU2009333433B2 (en) 2012-06-14

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009333433A Ceased AU2009333433B2 (en) 2008-12-17 2009-12-10 Compounds useful for inhibiting Chk1

Country Status (37)

Country Link
EP (1) EP2379532B1 (enExample)
JP (1) JP5705743B2 (enExample)
KR (1) KR101301777B1 (enExample)
CN (1) CN102245597B (enExample)
AR (1) AR074471A1 (enExample)
AU (1) AU2009333433B2 (enExample)
BR (1) BRPI0922468A2 (enExample)
CA (1) CA2746423C (enExample)
CL (1) CL2011001463A1 (enExample)
CO (1) CO6382122A2 (enExample)
CR (1) CR20110339A (enExample)
CY (1) CY1113930T1 (enExample)
DK (1) DK2379532T3 (enExample)
DO (1) DOP2011000185A (enExample)
EA (1) EA018118B1 (enExample)
EC (1) ECSP11011136A (enExample)
ES (1) ES2401558T3 (enExample)
HN (1) HN2011001446A (enExample)
HR (1) HRP20130167T1 (enExample)
IL (1) IL213160A (enExample)
JO (1) JO2886B1 (enExample)
MA (1) MA32901B1 (enExample)
MX (1) MX2011006603A (enExample)
MY (1) MY156998A (enExample)
NZ (1) NZ593440A (enExample)
PA (1) PA8850801A1 (enExample)
PE (1) PE20120077A1 (enExample)
PL (1) PL2379532T3 (enExample)
PT (1) PT2379532E (enExample)
RS (1) RS52739B (enExample)
SG (1) SG172222A1 (enExample)
SI (1) SI2379532T1 (enExample)
TN (1) TN2011000298A1 (enExample)
TW (1) TWI436996B (enExample)
UA (1) UA101998C2 (enExample)
WO (1) WO2010077758A1 (enExample)
ZA (1) ZA201103946B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
JO3145B1 (ar) * 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
TWI627168B (zh) * 2015-12-07 2018-06-21 美國禮來大藥廠 (s)-乳酸鹽
HK1254687A1 (zh) 2015-12-15 2019-07-26 Eli Lilly And Company 用於癌症的联合疗法
CA3013514C (en) 2016-02-04 2021-11-23 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
EP4067351B1 (en) * 2019-11-29 2025-01-22 NovaOnco JS Therapeutics Co., Ltd. Diazaindole derivative and use thereof as chk1 inhibitor
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
MX2023006364A (es) * 2020-11-30 2023-06-13 Sumitomo Pharma Co Ltd Derivado de 5-heteroaril-1h-pirazol-3-amina.
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
CA3241992A1 (en) 2021-12-24 2023-06-29 Seiji Kamioka 1h-pyrazole-3-amine derivative having bicyclic backbone
JP7546104B2 (ja) * 2022-05-27 2024-09-05 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬
JPWO2023229032A1 (enExample) * 2022-05-27 2023-11-30
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
GB202403910D0 (en) 2024-03-19 2024-05-01 Benovental Cambridge Ltd New processes and intermediates for pharmaceutical products
NL2039212B1 (en) 2024-12-02 2026-06-23 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Mitotic cell phase enrichment and ionizing radiation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009435A1 (en) * 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009435A1 (en) * 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer

Also Published As

Publication number Publication date
KR101301777B1 (ko) 2013-08-30
DOP2011000185A (es) 2017-12-15
JO2886B1 (en) 2015-03-15
CA2746423A1 (en) 2010-07-08
RS52739B (sr) 2013-08-30
IL213160A (en) 2013-12-31
MY156998A (en) 2016-04-15
MX2011006603A (es) 2011-09-27
CO6382122A2 (es) 2012-02-15
JP5705743B2 (ja) 2015-04-22
HK1160110A1 (en) 2012-08-10
IL213160A0 (en) 2011-07-31
PL2379532T3 (pl) 2013-07-31
MA32901B1 (fr) 2011-12-01
CY1113930T1 (el) 2016-07-27
ECSP11011136A (es) 2011-07-29
PE20120077A1 (es) 2012-02-06
CN102245597B (zh) 2014-04-16
HN2011001446A (es) 2013-08-05
EP2379532A1 (en) 2011-10-26
WO2010077758A1 (en) 2010-07-08
DK2379532T3 (da) 2013-03-18
CA2746423C (en) 2014-01-14
SI2379532T1 (sl) 2013-05-31
SG172222A1 (en) 2011-07-28
ZA201103946B (en) 2012-10-31
HRP20130167T1 (hr) 2013-03-31
TWI436996B (zh) 2014-05-11
JP2012512249A (ja) 2012-05-31
KR20110084539A (ko) 2011-07-25
ES2401558T3 (es) 2013-04-22
PT2379532E (pt) 2013-03-25
CL2011001463A1 (es) 2012-01-20
EP2379532B1 (en) 2013-02-20
AU2009333433A1 (en) 2011-06-30
BRPI0922468A2 (pt) 2020-08-04
UA101998C2 (ru) 2013-05-27
TW201029994A (en) 2010-08-16
CN102245597A (zh) 2011-11-16
EA018118B1 (ru) 2013-05-30
PA8850801A1 (es) 2010-07-27
AR074471A1 (es) 2011-01-19
CR20110339A (es) 2011-09-14
EA201170834A1 (ru) 2011-12-30
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
EP2379532B1 (en) Compounds useful for inhibiting chk1
JP6169185B2 (ja) キナーゼ阻害剤としての新規ベンゾイミダゾール誘導体
US8314108B2 (en) 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
KR101533166B1 (ko) Ｃｈｋ１ 억제에 유용한 화합물
JP2013510824A (ja) セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
US20190367520A1 (en) New compound having fgfr inhibitory activity and preparation and application thereof
CA2506773A1 (en) Heteroaryl-pyramidine derivatives as jak inhibitors
KR20130028732A (ko) 4―아미노피리미딘 유도체 및 아데노신 ａ2ａ 수용체 안타고니스트로서의 이들의 용도
JP2014141529A (ja) キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
US12558345B2 (en) CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas
WO2004087679A1 (en) 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
Zhang et al. Design, synthesis and biological evaluation of novel 4-aminopiperidine derivatives as SMO/ERK dual inhibitors
HK1160110B (en) Compounds useful for inhibiting chk1
US11660303B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
Anastassova et al. Novel 2-aminobenzimidazolyl-1-hydrazones with antileukemic activity: Potent alternatives to imatinib and ibrutinib

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired